spinal cord astrocytoma
Conditions
Interventions
Catheter implantation (day1) ACNU (0.25 mg/ml or lower)+ Gd-DOTA(1mM) infusion (day1-2) and TMZ (200mg/m2) p.o. (day1-5)
Sponsors
Tohoku University, Graduate school of medicine, Department of Neurosurgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) For those who suffer recurrent spinal cord astrocytoma and surgical treatment is not indicated. Cases include spinal cord originated tumors and disseminated lesion from intracranial astrocytoma. 2) For those who suffered recurrence after standard treatments including surgical removal, radiotherapy and chemotherapy. 3) For those who did not undertake any of the above mentioned treatment during the previous 4 weeks. 4) For those who have normal laboratory checkup. 5) For those who gave consent to be included in the exam.
Exclusion criteria
Exclusion criteria: 1) For those suffering other cancer 2) For those suffering meningitis or pneumonia 3) Pregnant or Lactating women 4) For those suffering inflammation 5) For those suffering liver dysfunction 6) For those suffering myelo -suppression 7) For those suffering kidney dysfunction 8) For those having bleeding tendency or undertaking anti-coagulation or anti-platelet therapy 9) For those suffering psychiatric disorder 10) For those suffering uncontrolled Diabetes mellius 11) For those who have history of cardiac infarction in the last three months, or suffering angina pectoralis 12) For those having history of Idiopathic pulmonary fibrosis or interstitial pneumonia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine maximum tolerable concentration of ACNU | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness, survival rate of 6 months, and overall survival | — |
Countries
Japan
Contacts
Public ContactToshiki Endo
Tohoku University Graduate School of Medicine Neurosurgery
Outcome results
None listed